Michael Okunewitch
Stock Analyst at Maxim Group
(0.62)
# 4,126
Out of 5,124 analysts
30
Total ratings
26.92%
Success rate
-15.96%
Average return
Main Sectors:
Stocks Rated by Michael Okunewitch
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VNRX VolitionRx | Downgrades: Hold | n/a | $0.27 | - | 1 | Dec 3, 2025 | |
| RANI Rani Therapeutics Holdings | Maintains: Buy | $5 → $10 | $1.36 | +635.29% | 1 | Oct 20, 2025 | |
| CTOR Citius Oncology | Upgrades: Buy | $6 | $1.08 | +455.56% | 3 | Sep 23, 2025 | |
| ANEB Anebulo Pharmaceuticals | Downgrades: Hold | n/a | $1.13 | - | 3 | Jul 23, 2025 | |
| HCWB HCW Biologics | Maintains: Buy | $120 → $35 | $1.12 | +3,025.00% | 2 | May 29, 2025 | |
| RADX Radiopharm Theranostics | Initiates: Buy | $12 | $5.16 | +132.56% | 1 | May 1, 2025 | |
| CMMB Chemomab Therapeutics | Maintains: Buy | $16 → $28 | $1.79 | +1,464.25% | 2 | Feb 20, 2025 | |
| MYNZ Mainz Biomed | Initiates: Buy | $14 | $1.16 | +1,106.90% | 1 | Feb 14, 2025 | |
| LCTX Lineage Cell Therapeutics | Maintains: Buy | $5 → $3 | $1.64 | +82.93% | 1 | Jan 10, 2025 | |
| OCGN Ocugen | Initiates: Buy | $4 | $1.38 | +189.86% | 1 | Oct 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $0.24 | +4,902.08% | 1 | Sep 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $6 | $0.59 | +911.80% | 2 | Aug 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $3 → $12 | $0.65 | +1,734.86% | 2 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $2.46 | +875.61% | 1 | Oct 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $18 | $2.02 | +791.09% | 3 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $2,025 | $1.90 | +106,478.95% | 1 | Apr 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $18.42 | +35.72% | 1 | Dec 22, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.22 | +391.80% | 1 | Sep 28, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $25 | $3.87 | +545.99% | 1 | Nov 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $100 | $0.85 | +11,692.45% | 1 | Nov 30, 2021 |
VolitionRx
Dec 3, 2025
Downgrades: Hold
Price Target: n/a
Current: $0.27
Upside: -
Rani Therapeutics Holdings
Oct 20, 2025
Maintains: Buy
Price Target: $5 → $10
Current: $1.36
Upside: +635.29%
Citius Oncology
Sep 23, 2025
Upgrades: Buy
Price Target: $6
Current: $1.08
Upside: +455.56%
Anebulo Pharmaceuticals
Jul 23, 2025
Downgrades: Hold
Price Target: n/a
Current: $1.13
Upside: -
HCW Biologics
May 29, 2025
Maintains: Buy
Price Target: $120 → $35
Current: $1.12
Upside: +3,025.00%
Radiopharm Theranostics
May 1, 2025
Initiates: Buy
Price Target: $12
Current: $5.16
Upside: +132.56%
Chemomab Therapeutics
Feb 20, 2025
Maintains: Buy
Price Target: $16 → $28
Current: $1.79
Upside: +1,464.25%
Mainz Biomed
Feb 14, 2025
Initiates: Buy
Price Target: $14
Current: $1.16
Upside: +1,106.90%
Lineage Cell Therapeutics
Jan 10, 2025
Maintains: Buy
Price Target: $5 → $3
Current: $1.64
Upside: +82.93%
Ocugen
Oct 15, 2024
Initiates: Buy
Price Target: $4
Current: $1.38
Upside: +189.86%
Sep 24, 2024
Initiates: Buy
Price Target: $12
Current: $0.24
Upside: +4,902.08%
Aug 27, 2024
Maintains: Buy
Price Target: $15 → $6
Current: $0.59
Upside: +911.80%
Mar 5, 2024
Maintains: Buy
Price Target: $3 → $12
Current: $0.65
Upside: +1,734.86%
Oct 5, 2023
Initiates: Buy
Price Target: $24
Current: $2.46
Upside: +875.61%
Aug 9, 2023
Maintains: Buy
Price Target: $108 → $18
Current: $2.02
Upside: +791.09%
Apr 12, 2023
Initiates: Buy
Price Target: $2,025
Current: $1.90
Upside: +106,478.95%
Dec 22, 2022
Initiates: Buy
Price Target: $25
Current: $18.42
Upside: +35.72%
Sep 28, 2022
Initiates: Buy
Price Target: $6
Current: $1.22
Upside: +391.80%
Nov 30, 2021
Initiates: Buy
Price Target: $25
Current: $3.87
Upside: +545.99%
Nov 30, 2021
Initiates: Buy
Price Target: $100
Current: $0.85
Upside: +11,692.45%